Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

A77 1726

Dihydrorotate dehydrogenase inhibitor
 
ALX-430-096-M005 5 mg 56.00 USD
 
ALX-430-096-M025 25 mg 217.00 USD
Do you need bulk/larger quantities?
 
Physiologically active metabolite of the immunosuppressive drug leflunomide (Prod. No. ALX-430-095). Inhibits the activity of dihydrorotate dehydrogenase and of protein tyrosine kinases. Blocks TNF-mediated NF-κB activation in a dose- and time-dependent manner. Also inhibits the activity of cyclooxygenase-2 (COX-2) in vitro and in vivo.

Product Specification

Alternative Name:N-(4-Trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide, 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide
 
Formula:C12H9F3N2O2
 
MW:270.1
 
CAS:108605-62-5
 
Purity:≥98% (HPLC)
 
Identity:Determined by NMR, IR and MS.
 
Appearance:White solid.
 
Solubility:Soluble in DMSO.
 
Shipping:Ambient
 
Long Term Storage:+4°C
 
Handling:Protect from light. Keep under inert gas.
 
ALX-430-096
Please mouse over
ALX-430-096

Product Literature References

A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner: L.C. Hamilton, et al.; Br. J. Pharmacol. 127, 1589 (1999), Abstract;
Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression: S.K. Manna & B.B. Aggarwal; J. Immunol. 162, 2095 (1999), Abstract;
In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice: X. Xu, et al.; J. Immunol. 159, 167 (1997), Abstract;
The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms: R.T. Elder, et al.; J. Immunol. 159, 22 (1997), Abstract;
The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase: J.P. Davis, et al.; Biochemistry 35, 1270 (1996), Abstract;
Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation: X. Xu, et al.; Biochem. Pharmacol. 52, 527 (1996), Abstract;
Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide: X. Xu, et al.; J. Biol. Chem. 270, 12398 (1995), Abstract; Full Text
Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide: T. Mattar, et al.; FEBS Lett. 334, 161 (1993), Abstract;

Related Products

Leflunomide 

Immunosuppressant
75706-12-6, ≥98.5% (HPLC) | Print as PDF
 
ALX-430-095-M050 50 mg 53.00 USD
 
ALX-430-095-G001 1 g 457.00 USD
Do you need bulk/larger quantities?
 

Related Literature

Brochures
Integrated solutions for screening Wnt regulators
Integrated solutions for screening Wnt regulators
Download as PDF

All new literature pieces

Recommend this page

 
Keep in touch

©2017 Enzo Life Sciences, Inc.,